Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDHB | P21912 | 9/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 5/20 | 0.60 |
| ▸ | HTT | P42858 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | STAT3 | P40763 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | STAT1 | P42224 | 2/20 | 0.60 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.60 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721292 | 0.81 | SDHB (0.81) | SDHBNPSR1HPGDLMNATP53 | |
| SCHEMBL1830578 | 0.77 | SDHB (0.65) | SDHBNPSR1HPGDLMNATP53 | |
| SCHEMBL5378591 | 0.76 | PTGS2 (0.74) | HPGDTP53KMT2AMEN1POLB | |
| SCHEMBL29975914 | 0.75 | NPSR1 (1.00) | SDHBNPSR1HPGDLMNATP53 | |
| SCHEMBL28307436 | 0.75 | NPSR1 (1.00) | SDHBNPSR1HPGDLMNATP53 | |
| SCHEMBL5373896 | 0.75 | PTGS2 (0.75) | HPGDLMNAKDM4EALDH1A1MAPT | |
| SCHEMBL18231250 | 0.75 | KCNH2 (0.55) | PTGS2 | |
| SCHEMBL19805665 | 0.74 | NPSR1 (1.00) | SDHBNPSR1HPGDLMNATP53 | |
| SCHEMBL19805673 | 0.74 | SDHB (1.00) | SDHBNPSR1HPGDLMNATP53 | |
| SCHEMBL19805627 | 0.74 | SDHB (0.63) | SDHBNPSR1HPGDLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235560-B2 | Pyrimidine derivative as selective COX-2 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235560-B2 | Pyrimidine derivative as selective COX-2 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235560-B2 | Pyrimidine derivative as selective COX-2 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| EP-1546128-B1 | PYRIMIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LTD (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20060040967-A1 | Pyrimidine derivative as selelctive cox-2 inhibitors | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1546128-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004018452-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040967-A1 | Pyrimidine derivative as selelctive cox-2 inhibitors | PTGES2, PTGS2, DPYD | SDHB 686/4885NPSR1 2443/4885HPGD 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.